https://www.taplowgroup.comInsight
https://www.taplowgroup.comTaplow
https://www.taplowgroup.comKnowledge
  • News
  • Cases
  • Downloads
Taplow Group – 9th 2020 Global Business Overview
05.10.2020

Taplow Group – 9th 2020 Global Business Overview

The Taplow firms have been active throughout the pandemic. This is the Ninth update in our Business Updates series from our partners around the...
Read more
Taplow Group – 8th Global Business Overview
31.08.2020

Taplow Group – 8th Global Business Overview

The Taplow firms have been active throughout the pandemic. This is the eighth in our Business Updates series from our partners around the...
Read more
Taplow Group – 7th Global Business Overview
27.07.2020

Taplow Group – 7th Global Business Overview

The Taplow firms have been active throughout the pandemic, this is the seventh in our Business Updates series from our partners around the world.
Read more
First78910111213141516Last

 CEO FOR A SPORTS:

Situation: A Finnish, mainly nationally operating sports company needed new CEO as the old one was about to retire. As sports business is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

 

 

 CEO FOR LOGISTICS:

Situation: One of the largest globally operating Logistics companies was in a need of new CIO for Finland. As Logistics and Value Chain is one of the competence areas of our Finnish partner, we ended up delivering this search.

Read more …

For further Information please contac Timo Toivanen, Finland

White Papers

  • India – The new R&D hub for Automotive

    Taplow India have conducted an in-depth review of the Automotive sector in India, For further information contact Sangeeta Sabharwal, India

    Click Here

  • Maysam Rizvi reviews the Banking Tech Revolution.

    Capital is more expensive, costs are higher and prices have gone down… the technology revolution has become a necessity.

    Click Here

  • EVOLVING BUSINESS UNITS Market Access thus becoming “transversal”

    The pharmaceutical market, in regards to the price component covered by the NHS, has been, until today, characterised by the presence of drugs of high therapeutic value, such as cancer-drugs, rheumatologic drugs, anti-infection drugs and drugs for the treatment of chronic illnesses, the vast majority of which have either seen their patent expire recently or will see it expire in the next two years.

    Click Here

  • BUSINESS CYCLES

    Present Human Capital Opportunities and Challenges:

    Click Here